麻豆视频

NICE is consulting on the Addendum to the

• will update NICE guideline
• covers care and support for people with advanced (stage 4) breast cancer.
• aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life.

Please note that NICE have also added a new recommendation on assessing oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status on disease recurrence. 

For further information or to provide feedback, please contact Caroline Rapu